Core Insights - Inhibikase Therapeutics is expanding its therapeutic pipeline with multiple late-stage development assets aimed at treating Parkinson's disease and related disorders [1][2] - The company anticipates completing the 201 Trial for untreated Parkinson's disease by the end of Q3 2024, with 94% enrollment achieved [2][5] - Inhibikase is seeking grant funding for the 202 Trial in Multiple System Atrophy through the National Institute of Neurological Diseases and Stroke [2][5] - The company is redirecting efforts for IkT-001Pro into cardiopulmonary disease, specifically targeting Pulmonary Arterial Hypertension, following a pre-IND meeting with the FDA [2][5] Company Overview - Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics for Parkinson's disease and related disorders [4] - The company's lead program, Risvodetinib, is an Abelson Tyrosine Kinase inhibitor targeting Parkinson's disease and other related conditions [4] - Inhibikase's pipeline includes treatments for neurodegeneration, orphan indications like Multiple System Atrophy, and drug delivery technologies [4] Upcoming Milestones - Completion of the 201 Trial in untreated Parkinson's disease is expected by the end of Q3 2024, with biomarker and outcome data to be reported by the end of 2024 [5] - The company plans to submit an IND application for IkT-001Pro for Pulmonary Arterial Hypertension in early Q3 2024 [5] - Inhibikase is scaling manufacturing processes for IkT-001Pro to support late-stage clinical development and NDA batch requirements [5] - The company will discontinue development of antiviral treatments for Progressive Multifocal Leukoencephalopathy to focus on late-stage clinical assets [5]
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs